
Chandler H Park MD FACP
Gastrointestinal Cancer, Genitourinary Oncology, Hematologic Oncology, Thoracic Cancer
•Advisory Dean University of Louisville School of Medicine •President Kentucky Society of Clinical Oncology (ASCO chapter) •Principal Investigator for Cancer Clinical Trials •3X NEJM Published Author •ASCO CME Faculty •ABIM Medical Oncology Exam Committee Task Force Advisor Neil Love, MedPro, OncLive •Cancer Physician serving patients in the greater Louisville, Kentucky area
676 South Floyd StreetSte 110Louisville, KY 40202
Phone+1 502-629-2500
Fax+1 502-629-2055
Dr. Park is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Chandler Park is an American physician, media correspondent, and clinical researcher. Park has been very fortunate to be published in the New England Journal of Medicine three times as a Principal Investigator and Author for original research in genitourinary cancer.
He has a passion for medical education. At the University of Louisville, he works as an Advisory Dean to help medical students during their medical school journey.
In terms of oncology education, Park hosts continuing medical education meetings to update physicians throughout the country by hosting CME programs in Nashville, Cleveland, Seattle, and Denver.
Park contributes regularly as an expert physician for popular newspapers and magazines such as Newsweek, Reader's Digest,U.S. News & World Report and Medscape. He is also the founder of Cancervisit.com a medical information company dedicated to helping cancer patients and their families.
Park is also a medical school professor at the University of Louisville School of Medicine. He is triple-board-certified in internal medicine, hematology and oncology. In 2016, he was recognized nationally by his physician colleagues as a distinguished fellow of the American College of Physicians (FACP) for providing outstanding patient care and significant medical research contributions.
Park is a practicing hematologist and oncologist that has won many patient satisfaction awards including Press Ganey.
He has also served as an assistant professor, attending hospitalist physician, and Chief Resident at Indiana University Health affiliated hospitals. He is an accomplished medical researcher having written many scientific research articles and manuscripts in leading medical journals.
His cancer research has been presented at leading cancer society meetings including his research on PET/CT and regional brain metabolic changes associated with depression in breast cancer patients at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2013 - 2014
West Virginia UniversityFellowship, Hematology and Medical Oncology, 2013 - 2014
Indiana University School of MedicineResidency, Internal Medicine, 2009 - 2011
Indiana University School of MedicineResidency, Radiology-Diagnostic, 2008 - 2009
Cleveland Clinic FoundationInternship, Internal Medicine, 2007 - 2008
Certifications & Licensure
IN State Medical License 2009 - 2027
KY State Medical License 2016 - 2027
WV State Medical License 2013 - 2017
OH State Medical License 2007 - 2011
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America’s Top Oncologist Castle Connolly, 2019-2024
- America’s Top Doctor Castle Connolly Top Doctors, 2019-2024
- CME Faculty ASCO (American Society of Clinical Oncology), 2018-2022
Clinical Trials
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2018 May 29
- The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC Start of enrollment: 2019 May 30
- Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer. Start of enrollment: 2020 Jul 31
Publications & Presentations
PubMed
- Evolving Therapeutic Algorithms in Chronic Myeloid Leukemia: Integrating Efficacy, Safety, and Survivorship.Yan Leyfman, Ahmed Hashim Azeez, Taha Kassim Dohadwala, Soumiya Nadar, Riya Vaishnav
Biomedicines. 2026-02-11 - Empowering Global Hematology-Oncology Education: Assessing the Impact of a Virtual Platform in Combating Educational Inequity.Yan Leyfman, Viviana Cortiana, Maduri Balasubramanian, Gayathri Pramil Menon, Muskan Joshi
JCO Global Oncology. 2025-11-01 - Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey.Enrique Grande, Joaquim Bellmunt, Syed A Hussain, Mubarak M Al Mansour, Aristotle Bamias
The Oncologist. 2025-10-01
Journal Articles
- Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic ur...Petros Grivas, Damien Pouessel, Chandler H. Park, Philippe Barthelemy, Manojkumar Bupathi, Daniel P. Petrylak, Neeraj Agarwal et al, Journal of Clinical Oncology 2023 41:6_suppl, 518-518, 2/23/2023
- Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (m...Daniel P. Petrylak, Scott T. Tagawa, Rohit K. Jain, Chandler Park et al, Journal of Clinical Oncology 2023 41:6_suppl, 520-520, 2/22/2023
- Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate CancerMatthew R. Smith, M.D., Ph.D., Maha Hussain, M.D., Fred Saad, M.D., Chandler H. Park, M.D., Boris Alekseev, M.D., Hiroyoshi Suzuki, M.D., Ph.D., Bertrand Tombal, M.D.,..., New England Journal of Medicine, 2/17/2022
Lectures
- PET/CT and Regional Brain Metabolic Changes Associated with Depression in Metastatic Breast Cancer1/1/2016
- Sorafenib and thyroid cancer1/1/2014
- Sunitinib As the "Second Hit" In Acute Esophageal Necrosis1/1/2014
Other
- Course Director - Masters Lecture Series in OncologyChandler Park M.D., MedPro
https://web.cvent.com/event/80286cdc-ff79-484f-8ec7-192d878c433c/websitePage:23100ac0-62ab-4616-85eb-8e1e4d0b7982
Las Vegas - 2/27/2022 - Course Director- MedPro Cancer MeetingChandler Park MD
https://www.accc-cancer.org/docs/ossn-network/tn/meetings/ascoreviewnashvillefacultylist.pdf
6/2021 - Course Director- Society of Immunotherapy in CancerChandler Park MD, SITC
https://www.sitcancer.org/education/aci/2020-21/louisville
Louisville, Kentucky - 12/2020
Authored Content
- 2020 Bladder Cancer Review with Dr. Petros Grivas: What Every Physician Should KnowDecember 2020
- ESMO 2020: What's New with Prostate Cancer TreatmentOctober 2020
- ESMO 2020: What Every Physician Should KnowSeptember 2020
Press Mentions
Dr. Park Considers Long-Term Data for Frontline Metastatic ccRCC TreatmentNovember 24th, 2023
Future Outlook of Kidney Cancer TreatmentOctober 25th, 2023
Advice for Patients with Advanced Renal Cell CarcinomaOctober 25th, 2023
Committees
- Advisory Board and Selection Committee Member, Giants of Cancer Care 2019 - Present
- Continuing Medical Education Committee, American Society of Clinical Oncology 2018 - Present
- Board Member, Leukemia and Lymphoma Society (LLS) Executive Board for Kentucky and Indiana 2016 - Present
Research History
- Principal InvestigatorPrincipal Investigator for clinical trials in genitourinary cancers that include kidney, bladder, and prostate cancer.2019 - Present
Professional Memberships
- Member
- Member
- Fellow
External Links
- Facebookhttp://ChandlerParkMD.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:












